Technical Analysis for MPH - Medicure Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.880 | 0.00% | 0.000 |
Earnings due: Nov 19
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Volume Surge | Other | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 18 days ago |
| Down 3% | 18 days ago |
| Down 2% | 18 days ago |
| Down 1% | 18 days ago |
| Fell Below Lower Bollinger Band | 18 days ago |
Get a Trading Sidekick!
- Earnings date: 2024-11-19
Medicure Inc. Description
Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Marketing Medicine Pharma Pharmaceutical Clinic Drug Skin Biopharmaceutical Organ Systems Pharmaceutical Industry Disorders Cardiology Neurological Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.8 |
| 52 Week Low | 0.88 |
| Average Volume | 5,314 |
| 200-Day Moving Average | 1.271 |
| 50-Day Moving Average | 1.046 |
| 20-Day Moving Average | 0.977 |
| 10-Day Moving Average | 0.935 |
| Average True Range | 0.045 |
| RSI (14) | 37.89 |
| ADX | 8.32 |
| +DI | 33.943 |
| -DI | 40.735 |
| Chandelier Exit (Long, 3 ATRs) | 1.015 |
| Chandelier Exit (Short, 3 ATRs) | 1.015 |
| Upper Bollinger Bands | 1.093 |
| Lower Bollinger Band | 0.860 |
| Percent B (%b) | 0.09 |
| BandWidth | 23.820 |
| MACD Line | -0.047 |
| MACD Signal Line | -0.037 |
| MACD Histogram | -0.0103 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.895 | ||||
| Resistance 3 (R3) | 0.897 | 0.893 | 0.893 | ||
| Resistance 2 (R2) | 0.893 | 0.890 | 0.893 | 0.892 | |
| Resistance 1 (R1) | 0.887 | 0.887 | 0.885 | 0.885 | 0.891 |
| Pivot Point | 0.883 | 0.883 | 0.883 | 0.883 | 0.883 |
| Support 1 (S1) | 0.877 | 0.880 | 0.875 | 0.875 | 0.869 |
| Support 2 (S2) | 0.873 | 0.877 | 0.873 | 0.868 | |
| Support 3 (S3) | 0.867 | 0.873 | 0.868 | ||
| Support 4 (S4) | 0.865 |
